172 related articles for article (PubMed ID: 9156364)
41. Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.
Jones RL; Wise H; Clark R; Whiting RL; Bley KR
Br J Pharmacol; 2006 Sep; 149(1):110-20. PubMed ID: 16880763
[TBL] [Abstract][Full Text] [Related]
42. Characterization of chimeric prostacyclin/prostaglandin D(2) receptors.
Wise H
Eur J Pharmacol; 1999 Dec; 386(1):89-96. PubMed ID: 10611468
[TBL] [Abstract][Full Text] [Related]
43. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Gatfield J; Menyhart K; Wanner D; Gnerre C; Monnier L; Morrison K; Hess P; Iglarz M; Clozel M; Nayler O
J Pharmacol Exp Ther; 2017 Jul; 362(1):186-199. PubMed ID: 28476928
[TBL] [Abstract][Full Text] [Related]
44. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.
Clapp LH; Finney P; Turcato S; Tran S; Rubin LJ; Tinker A
Am J Respir Cell Mol Biol; 2002 Feb; 26(2):194-201. PubMed ID: 11804870
[TBL] [Abstract][Full Text] [Related]
45. The effect of prostacyclin mimetics on neutrophil function.
Wise H
Adv Exp Med Biol; 1997; 407():261-4. PubMed ID: 9321962
[No Abstract] [Full Text] [Related]
46. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
Fuchikami C; Murakami K; Tajima K; Homan J; Kosugi K; Kuramoto K; Oka M; Kuwano K
Eur J Pharmacol; 2017 Jan; 795():75-83. PubMed ID: 27919660
[TBL] [Abstract][Full Text] [Related]
47. Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety.
Meanwell NA; Rosenfeld MJ; Trehan AK; Romine JL; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M
J Med Chem; 1992 Sep; 35(19):3498-512. PubMed ID: 1404231
[TBL] [Abstract][Full Text] [Related]
48. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension.
Shen L; Patel JA; Norel X; Moledina S; Whittle BJ; von Kessler K; Sista P; Clapp LH
Biochem Pharmacol; 2019 Aug; 166():242-252. PubMed ID: 31158340
[TBL] [Abstract][Full Text] [Related]
49. The effect of non-prostanoid prostacyclin mimetics on cyclic AMP production by neuronal SK-N-SH cells.
Wise H; Chow KB
Adv Exp Med Biol; 1997; 433():197-200. PubMed ID: 9561134
[No Abstract] [Full Text] [Related]
50. Neuronal stimulant actions of prostacyclin and its novel mimetics.
Jones RL; Qian YM; Tam FS; Chan KM; Kin AP; Ho JK; Bourreau JP
Adv Exp Med Biol; 1997; 407():211-7. PubMed ID: 9321955
[No Abstract] [Full Text] [Related]
51. Prostaglandin I2 and prostaglandin E2 modulate human intrarenal artery contractility through prostaglandin E2-EP4, prostacyclin-IP, and thromboxane A2-TP receptors.
Eskildsen MP; Hansen PB; Stubbe J; Toft A; Walter S; Marcussen N; Rasmussen LM; Vanhoutte PM; Jensen BL
Hypertension; 2014 Sep; 64(3):551-6. PubMed ID: 24914192
[TBL] [Abstract][Full Text] [Related]
52. Nonprostanoid prostacyclin mimetics. 2. 4,5-Diphenyloxazole derivatives.
Meanwell NA; Rosenfeld MJ; Trehan AK; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M; Zavoico GB
J Med Chem; 1992 Sep; 35(19):3483-97. PubMed ID: 1404230
[TBL] [Abstract][Full Text] [Related]
53. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
Meja KK; Barnes PJ; Giembycz MA
Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
[TBL] [Abstract][Full Text] [Related]
54. Regulation of prostacyclin and prostaglandin E(2) receptor mediated responses in adult rat dorsal root ganglion cells, in vitro.
Rowlands DK; Kao C; Wise H
Br J Pharmacol; 2001 May; 133(1):13-22. PubMed ID: 11325789
[TBL] [Abstract][Full Text] [Related]
55. Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesion.
Darius H; Binz C; Veit K; Fisch A; Meyer J
J Am Coll Cardiol; 1995 Sep; 26(3):800-6. PubMed ID: 7543911
[TBL] [Abstract][Full Text] [Related]
56. Pharmacological characterization in vitro of prostanoid receptors in the myometrium of nonpregnant ewes.
Crankshaw DJ; Gaspar V
J Reprod Fertil; 1995 Jan; 103(1):55-61. PubMed ID: 7535849
[TBL] [Abstract][Full Text] [Related]
57. Characterization of the prostanoid receptors mediating constriction and relaxation of human isolated uterine artery.
Baxter GS; Clayton JK; Coleman RA; Marshall K; Sangha R; Senior J
Br J Pharmacol; 1995 Sep; 116(1):1692-6. PubMed ID: 8564239
[TBL] [Abstract][Full Text] [Related]
58. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
Whittle BJ; Silverstein AM; Mottola DM; Clapp LH
Biochem Pharmacol; 2012 Jul; 84(1):68-75. PubMed ID: 22480736
[TBL] [Abstract][Full Text] [Related]
59. Activation of prostanoid EP receptors by prostacyclin analogues in rabbit iliac artery: implications for anti-restenotic potential.
McCormick C; Jones RL; Kennedy S; Wadsworth RM
Eur J Pharmacol; 2010 Sep; 641(2-3):160-7. PubMed ID: 20450909
[TBL] [Abstract][Full Text] [Related]
60. Differential activation of Gi and Gs proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL.
Schwaner I; Offermanns S; Spicher K; Seifert R; Schultz G
Biochim Biophys Acta; 1995 Feb; 1265(1):8-14. PubMed ID: 7532011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
